Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Emerging Technologies for Diagnostics & Liquid Biopsies - New Orleans 2024

Tony Hu's Biography



Tony Hu, Professor and Weatherhead Presidential Chair, Tulane University School of Medicine

Dr. Tony Hu is a Professor in Biochemistry and Molecular Biology, Biomedical Engineering, and Microbiology at Tulane University. He is also the Weatherhead Presidential Chair in Biotechnology Innovation, founding Director of the Center for Intelligent Molecular Diagnostics at Tulane School of Medicine, and the fellows of National Academy of Inventors (NAI) and American Institute of Medical and Biological Engineering (AIMBE). Dr. Hu’s research focuses on engineered multi-omics, nanomedicine, mechanism-driven biomarker discovery and assay development. His research differs from conventional biomarker discovery and detection research for clinical microbiology in that it employs the special properties of nanomaterials to improve assay performance and reproducibility. His inventions are intended to serve as a model for the analysis of similar characteristics of infectious and malignant diseases to facilitate the development of a full spectrum of diagnostic, prognostic and treatment evaluation assays, and re-define the diagnostic criteria to differentiate disease stages using molecular tests as a long-term goal. His work has resulted in publications of over 150 high-impact papers, and 25 pat¬ent applications involving nanomedicine. Fourteen of those patents have been licensed by US-based or international companies. Dr. Hu’s lab has been consistently support¬ed by the DOD, NIH, Gates Foundation, WHO and others. Dr. Hu is also the co-founders of two biotech startup companies, Intelligenome Inc. in Houston, TX and NanoPin Technologies in New Orleans, LA.

Tony Hu Image

EV-based Omics Analysis Enabling Personalized Diagnosis

Thursday, 26 September 2024 at 16:00

Add to Calendar ▼2024-09-26 16:00:002024-09-26 17:00:00Europe/LondonEV-based Omics Analysis Enabling Personalized DiagnosisEmerging Technologies for Diagnostics and Liquid Biopsies - New Orleans 2024 in New OrleansNew OrleansSELECTBIOenquiries@selectbiosciences.com

Diagnostics for infectious and malignant diseases often exhibit poor specificity/sensitivity, hindering early detection and treatment evaluation, but development of improved assays is limited by several challenges, including absence of disease-specific factors, low biomarker concentrations, and interfering factors. We have employed an array of sensitive analytic technology platforms to identify key host-pathogen interactions that influence pathogenesis and applies this information to identify diagnostic and predictive biomarkers that can be applied for personalized medicine to improve patient outcomes. We reported the development and validation of several nanotechnoloy-based assays platforms that can be used to quantify protein and nucleic acid changes in EV-associated protein biomarkers, and which have the capacity to target EVs derived from specific cell populations, including EVs derived from Mtb-infected phagocytes and other cell populations involved in granuloma formation. Candidate biomarkers identified will be analyzed using these platforms and correlated with changes in specific granuloma and systemic cell populations.


Add to Calendar ▼2024-09-26 00:00:002024-09-27 00:00:00Europe/LondonEmerging Technologies for Diagnostics and Liquid Biopsies - New Orleans 2024Emerging Technologies for Diagnostics and Liquid Biopsies - New Orleans 2024 in New OrleansNew OrleansSELECTBIOenquiries@selectbiosciences.com